HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer|Metastatic Cervical Cancer
Interventions: DIAGNOSTIC_TEST: Almac HER-Seq Assay
Sponsor: Puma Biotechnology, Inc.